ReviewCurrent hypertension reports2019
Pro-inflammatory Cytokines and Resistant Hypertension: Potential for Novel Treatments?
Review in Current hypertension reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Higher dietary inflammatory index linked to increased risk of hypertension: a systematic review and dose-response meta-analysis.European journal of clinical nutrition · 2025Pooled it
- The role of inflammatory biomarkers in the development and progression of pre-eclampsia: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Clonal hematopoiesis in apparent treatment-resistant hypertension, insights from multiple medical centers and community-based cohorts.Nature aging · 2025Article
- Association and interaction analysis of NLRP3 gene polymorphisms with hypertension risk: a case-control study in China.BMC cardiovascular disorders · 2024Article
- Vascular Inflammation and Smooth Muscle Contractility: The Role of Nox1-Derived Superoxide and LRRC8 Anion Channels.Hypertension (Dallas, Tex. : 1979) · 2024Review
- Prognostic nutritional index as a predictor of cardiovascular and all-cause mortality in American adults with hypertension: results from the NHANES database.Frontiers in cardiovascular medicine · 2024Article
- Humoral Cytokine Levels in Patients with Herpes Zoster: A Meta-Analysis.Journal of pain research · 2024Review
- LRRC8A anion channels modulate vascular reactivity via association with myosin phosphatase rho interacting protein.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Non-pharmacological interventions for vascular health and the role of the endothelium.European journal of applied physiology · 2022Review
- Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.Journal of personalized medicine · 2022Review
- Association of a pro-inflammatory diet with type 2 diabetes and hypertension: results from the Ravansar non-communicable diseases cohort study.Archives of public health = Archives belges de sante publique · 2022Article
- Inflammatory cytokines are associated to lower glomerular filtration rate in patients with hypertensive crisis.Frontiers in cardiovascular medicine · 2022Article
- Depletion and Dysfunction of Dendritic Cells: Understanding SARS-CoV-2 Infection.Frontiers in immunology · 2022Review
- Role of the central renin‑angiotensin system in hypertension (Review).International journal of molecular medicine · 2021Review
- Review
- Article
- RAAS-Blockade in COVID-19: The Ace of Spades?Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo gather data from studies evaluating the pro-inflammatory profile of individuals with resistant hypertension (RH), and bring a clinical update of new and potential complementary therapies to treat inflammation in RH. RECENT
findingsIncreases in pro-inflammatory cytokines are related to elevated blood pressure and target organ damage in RH patients. Clinical and experimental studies have shown that some biological therapies, especially TNF-α inhibitors, regulated pro- and anti-inflammatory cytokines associated with improvements in clinical outcomes, although they are not yet reported in RH. New emerging therapies to treat inflammation in RH, although promising, are still hypotheses that have not been scientifically confirmed in clinical trials. For this reason, inflammation-target treatments, such as the TNF-α and IL-6 inhibitors, should be encouraged for testing as complementary therapies in RH in order to elucidate their potential benefits.
Indexed as
Identifiers
31773311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.